ReviewRheumatology advances in practice2025
The prediction of response to treatment using power Doppler in rheumatoid arthritis: a systematic review.
Review in Rheumatology advances in practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Biomarkers of treatment response in rheumatoid arthritis: from conventional markers to tissue immunophenotype.Frontiers in immunology · 2026Review
- Immunological heterogeneity in rheumatoid arthritis: challenges in early-stage stratification, non-response to targeted therapy, and the restoration of immune tolerance.Frontiers in immunology · 2026Review
- Physician global assessment in rheumatoid arthritis-is there any logic?Rheumatology advances in practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: There is no consensus on how musculoskeletal ultrasound (US), especially power Doppler (PD) positivity, should inform treatment decisions in RA. We aimed to summarize the literature on whether PD positivity can predict response to intensification of RA therapies in patients with moderate to high clinical disease activity. Methods: A systematic literature review was performed using a predefined PICO strategy. The titles and abstracts, and subsequently full texts, were independently screened and reviewed by two reviewers and any disagreement was resolved by a third investigator. Studies that investigated the predictive value of PD were included. Results: Among 2580 abstracts/titles, 13 studies were included. Studies were heterogeneous regarding the inclusion criteria, baseline and new treatments, scanned joints and follow-up duration. In eight studies, patients with higher baseline PD activity had a better response to treatment, mostly with higher reductions in clinical indices. In contrast, two studies found that the probability of achieving clinical remission decreased as the baseline PD score increased. There was no association between baseline PD and the achievement of clinical remission at the follow-up in the remaining three studies. Conclusion: The baseline Doppler severity may suggest better improvement with higher reductions in composite scores, but this may not be enough to predict a remission state. How US can be used to predict response in RA management requires a well-designed study that will need to be shaped by the existing observations, most importantly identifying the outcome measure that will also be important for daily practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.